04:31 PM EDT, 09/24/2024 (MT Newswires) -- Amgen ( AMGN ) said late Tuesday that Japan's Ministry of Health, Labour and Welfare has approved Tepezza, or teprotumumab, for the treatment of active thyroid eye disease.

Tepezza has also been approved in the US, Brazil and Saudi Arabia, and is under regulatory review in Europe, Canada and Australia, the drugmaker said.

A second phase 3 clinical trial evaluating Tepezza in adults with chronic thyroid eye disease is ongoing in Japan, the company said.

Price: 332.24, Change: +1.32, Percent Change: +0.40